Stay updated with breaking news from Ilenec Weitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pegcetacoplan is as efficacious as eculizumab in paroxysmal nocturnal haemoglobinuria according to a recent study published in the Lancet. In the PEGASUS trial, the complement C3 inhibitor, ...
email article Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were still anemic despite at least three months of eculizumab therapy. The data were presented at December's In this exclusive MedPage Today video, study co-author Ilene C. Weitz, MD, of Keck School of Medicine at the University of Southern California, discusses the trial's findings. Following is a transcript of her remarks: The PEGASUS study was a study designed to lo...